startup

ChromoTek

Development and commercialization of Nanobody-based reagents.
  • Chemicals/Pharmaceuticals
  • Steady Stage
  • Manufacturing
  • B2B
  • 2008
  • 11-50 Employees
  • Found
  • Martinsried, DE
  • chromotek.com
  • ChromoTek GmbH
  • Bayern

Profile is not claimed et

This profile is created by the Startbase Analyst Team. If you are a team member of this company you can claim the profile in order to make changes to it.

Is this your company? Claim profile

About the Team

Are you part of this team?

Management

Marion Jung Geschäftsführerin
since 2011

Alumni

2008 - 2011
3 years, 1 months 		Ulrich Rothbauer
Geschäftsführer

News about ChromoTek

Recent mentions of ChromoTek in podcasts & videos:

Jobs at ChromoTek:

Related companies

aquila biolabs
Startup 2014 Baesweiler
aquila biolabs
Solutions for online biomass monitoring & feeding in shake flasks & bioreactors.
Genequine Biotherapeutics
Startup 2012 Hamburg
Genequine Biotherapeutics
Development of gene therapy drugs for the treatment of osteoarthritis.
Phenex Pharmaceuticals
Startup 2019 Heidelberg
Phenex Pharmaceuticals
Dynamic Biosensors
Startup 2011 Martinsried
Dynamic Biosensors
Supplier of equipment, consumables and services in the field of analytical systems for the characterization of biomolecules and molecular interactions.
BioNTech
Startup 2008 Mainz
BioNTech
Development of novel therapies against cancer & infectious diseases.

Other Startups nearby

Dust BioSolutions
Startup 2011 Martinsried
Dust BioSolutions
Dust BioSolutions is a start-up company focusing on industrial applications of biotechnology.
GNA Biosolutions
Startup 2010 Martinsried
GNA Biosolutions
Developing instruments, OEM modules and tests for the ultrafast, molecular biological detection of a wide range of pathogens. The core is a specially developed technology called laser PCR.
Eisbach
Startup 2019 Planegg-Martinsried
Eisbach
Development of drugs targeting chromatin regulatory mechanisms important for tumors.
Lindis Biotech
Startup 2010 Planegg
Lindis Biotech
Development of Triomab® antibodies - a new class of T-cell activating bispecific antibodies that enable the immune system to transform malignant cancers into treatable and potentially curable diseases.
Bind-X
Startup 2013 Planegg
Bind-X
Industrial applications in the field of biotechnology.

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen